Comparator Sourcing in Clinical Trials: Reframing a Systemic Risk in Global Study Execution
Comparator sourcing gets treated as a checkbox. Veljko Gucic, EVP Clinical Trial Services, argues it's actually one of the biggest hidden risks to trial timelines and success.
Originally published in International Clinical Trials (ICT) Magazine.
The increasing globalization and complexity of clinical trials have intensified the operational demands placed on sponsors and contract research organizations (CROs). While substantial attention has been directed toward protocol design, patient recruitment, and regulatory approval pathways, comparatively less focus has been given to comparator sourcing, despite its direct impact on trial timelines, cost structures, and data integrity.
Comparators, defined as commercially available medicinal products used as reference treatments, are integral to clinical study design and regulatory evaluation. However, unlike investigational medicinal products (IMPs), comparators are subject to external market forces, fragmented regulatory environments, and heterogeneous supply chains. These characteristics introduce a level of variability that is frequently underestimated in trial planning.¹
This article examines comparator sourcing as a systemic risk domain, identifies key drivers of complexity, and outlines a framework for transitioning toward a more integrated and anticipatory sourcing model.
Comparator Sourcing as a Multidimensional Risk Function
Comparator sourcing is often operationalized as a procurement activity. However, this characterization overlooks the extent to which sourcing decisions are intertwined with regulatory compliance, supply chain design, and financial planning.
From an operational standpoint, comparator sourcing must reconcile four interdependent dimensions: market dynamics, including availability constraints and pricing volatility; regulatory frameworks that govern labeling, importation, and clinical use; supply chain architecture encompassing procurement, storage, and distribution; and study design requirements such as dosing, packaging, and geographic scope.
The interaction between these dimensions creates a complex risk environment. For example, a sourcing strategy optimized for cost may introduce regulatory or logistical constraints that compromise timelines. Conversely, a strategy focused solely on availability may significantly exceed budget assumptions.
Industry analyses suggest that comparator sourcing challenges frequently arise from misalignment across these domains rather than isolated supply failures.²
Systemic Underestimation of Comparator Risk
The persistent underestimation of comparator sourcing risk can be attributed to three structural factors.
First, comparator sourcing is often initiated late—after protocol finalization or site activation—when the ability to adjust strategies is limited and organizations are forced into reactive responses.
Second, responsibility for comparator sourcing is typically fragmented across procurement, clinical operations, and regulatory functions. This fragmentation reduces visibility and impedes coordinated decision-making.
Third, there is a prevailing assumption that commercially available products can be procured with relative ease. In practice, this overlooks variability in pack configurations, national distribution controls, and regulatory requirements for clinical use.²
Together, these factors contribute to a structural bias toward underestimating comparator-related risks.
Core Risk Domains in Comparator Sourcing
Availability Constraints
Availability remains a primary risk driver, particularly in therapeutic areas characterized by limited production capacity or high demand, such as oncology and rare diseases. Products that are theoretically available in commercial markets may not be accessible in the required strength, formulation, pack size, geographic region, or timeframe. Additionally, national procurement systems and parallel trade restrictions can further constrain supply.³
Pricing Volatility
Comparator pricing is inherently dynamic and influenced by multiple external variables, including national tender outcomes, reimbursement policy changes, supply-demand imbalances, and market exclusivity periods. In certain therapeutic areas, pricing fluctuations can exceed initial budget estimates by a significant margin. Without continuous market monitoring, these changes may only become apparent after financial commitments have been established.⁴
Regulatory Heterogeneity
Regulatory requirements for comparator use vary across jurisdictions, particularly with respect to secondary packaging and labeling, import/export licensing, documentation standards, and Good Manufacturing Practice (GMP) compliance. These variations necessitate localized sourcing and adaptation strategies, making a standardized global approach rarely feasible.⁵
Supply Chain Fragmentation
The use of multiple vendors for sourcing, packaging, and distribution introduces coordination challenges and reduces accountability. Fragmented supply chains are associated with increased communication delays, reduced transparency, a higher likelihood of execution errors, and slower issue resolution. In complex, multi-country trials, these inefficiencies can accumulate and significantly impact timelines.
Toward a Strategic Sourcing Paradigm
Addressing comparator sourcing risk requires a shift from reactive procurement to proactive, integrated planning.
Early integration of comparator sourcing into trial design enables availability mapping across target geographies, preliminary pricing benchmarks, regulatory feasibility assessments, and the identification of alternative sourcing strategies. In this way, sourcing becomes a design parameter rather than a constraint.
The incorporation of real-time data—particularly in relation to pricing, supplier availability, and regulatory changes—supports more adaptive decision-making. Predictive analytics can help anticipate supply shortages, identify pricing trends, and optimize inventory strategies, reducing reliance on static assumptions and enhancing responsiveness.
Integrated sourcing models, characterized by a single point of accountability across procurement, packaging, and distribution, have been shown to improve execution reliability. These models enable faster decision-making, improved risk visibility, streamlined communication pathways, and stronger alignment between functional teams. Reducing handoffs is particularly important in high-complexity studies.
Implications of Global Trial Expansion
The expansion of clinical trials into diverse geographic regions has amplified comparator sourcing challenges. Each additional country introduces distinct regulatory requirements, unique import/export constraints, variability in product availability, and additional logistical considerations.
Global trials also often involve temperature-sensitive products with limited shelf life, increasing the importance of precise supply chain coordination.⁶ Geopolitical factors and broader supply chain disruptions further complicate planning, underscoring the need for resilient sourcing strategies.
Supply Chain Design as a Risk Mitigation Tool
Comparator sourcing must be considered within the broader context of clinical supply chain design. Within this framework, several core design elements must be aligned to ensure resilience and responsiveness:
Inventory Optimization: Balancing inventory levels is critical to minimizing both waste and stockout risk. This requires alignment between enrollment forecasts, production schedules, and distribution timelines.
Depot Strategy: Strategic placement of inventory in regional depots can reduce transit times, improve responsiveness, and minimize temperature excursions. Hybrid models that combine centralized oversight with localized distribution offer a balance between control and flexibility.
Quality Governance: Quality assurance must be embedded across all stages of the supply chain, including continuous monitoring of storage and transport conditions, real-time deviation management, and alignment with regulatory standards. Effective governance reduces compliance-related delays and ensures product integrity.
From Reactive Management to Predictive Planning
The transition from reactive to predictive sourcing models represents a fundamental shift in clinical trial operations. Predictive approaches emphasize early risk identification, scenario planning, continuous monitoring, and adaptive execution.
Early engagement in comparator sourcing significantly improves the ability to mitigate downstream risks.² Organizations that adopt predictive models are better positioned to manage uncertainty and maintain trial continuity.
Conclusion
Veljko (Vel) Gucic
EVP
of Clinical Trial Services
Vel Gucic is the EVP of Clinical Trial Solutions at Tanner Pharma. He leads the global CTS division, overseeing operations, growth strategy, and service delivery across clinical-trial support services, GMP packaging and labeling, comparator sourcing, and global distribution. Vel is a member of the Senior Management Team, aligning divisional performance with Tanner’s mission to expand global access to medicines.
Comparator sourcing is a critical yet underrecognized component of clinical trial execution. Its complexity arises from the intersection of market dynamics, regulatory variability, and supply chain design.
As clinical trials become increasingly global and resource-intensive, the limitations of traditional, transactional sourcing approaches are becoming more apparent. A strategic shift toward early integration, data-driven decision-making, and end-to-end accountability is essential to mitigate risk and improve outcomes.
Reframing comparator sourcing as a core strategic function, rather than a downstream procurement task, will be central to improving efficiency, predictability, and trial success.
References
1. International Clinical Trials (ICT), readership and industry positioning data.
2. IQVIA Institute. Global Trends in Clinical Trial Activity.
3. European Medicines Agency (EMA). Guidelines on Investigational Medicinal Products.
4. OECD. Pharmaceutical Pricing Policies in a Global Market.
5. U.S. Food and Drug Administration (FDA). Clinical Trial Supply Chain Considerations Guidance.
6. GlobalData Healthcare. Clinical Trial Supply Chain and Comparator Sourcing Insights.